Oruka Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 533 shares of common stock on September 21, 2026 for $95.75 per share.
NASDAQ
Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on September 21, 2026.
NASDAQ
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,947 shares of common stock on September 15, 2026.
NASDAQ
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,019 shares of common stock on September 11, 2026.
NASDAQ
Lawrence Otto Klein, Chief Executive Officer and a Director of Oruka Therapeutics, Inc., sold 2,452 shares of common stock on September 15, 2026 for $95.71 per share.
NASDAQ
Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 1,039 shares of common stock on September 15, 2026 for $95.71 per share.
NASDAQ
Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics, Inc., sold 906 shares of common stock on September 15, 2026 for $95.71 per share.
NASDAQ
Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics, Inc., sold 5,000 shares of common stock on September 1, 2026.
NASDAQ
Lawrence Otto Klein, Chief Executive Officer and a Director of Oruka Therapeutics, Inc., sold 75,000 shares of common stock on September 1, 2026.
NASDAQ
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on August 17, 2026.
NASDAQ
Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 52,000 shares of common stock on August 14, 2026.
NASDAQ
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on August 13, 2026.
NASDAQ
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on July 15, 2026.
NASDAQ
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 9,999 shares of common stock on July 13, 2026.
NASDAQ
Fairmount Funds Management LLC, along with affiliated entities, has converted a significant portion of Series B Preferred Stock into common stock of Oruka Therapeutics, Inc.
NASDAQ
Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock.
NASDAQ
Senior Vice President of Finance Arjun Agarwal exercised stock options and sold shares of Oruka Therapeutics under a 10b5-1 plan.
NASDAQ
Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a 10b5-1 plan.
NASDAQ
CEO Lawrence Klein sold 1,729 shares of Oruka Therapeutics to satisfy tax obligations related to RSU vesting.
NASDAQ
Oruka Therapeutics Chief Operating Officer Laura Lee Sandler sold 600 shares of common stock to satisfy tax obligations.
NASDAQ
General Counsel Paul T. Quinlan sold 733 shares of Oruka Therapeutics to satisfy tax obligations related to RSU vesting.
NASDAQ
Director Carl Dambkowski sold 35,000 shares of Oruka Therapeutics, Inc. common stock via a pre-arranged 10b5-1 trading plan.
NASDAQ
Oruka Therapeutics Director Carl Dambkowski acquired stock options for 9,136 shares of common stock.
NASDAQ
Oruka Therapeutics Director Samarth Kulkarni acquired stock options for 9,136 shares, with vesting commencing June 2, 2026.
NASDAQ
Oruka Therapeutics Director Christopher Martin acquired stock options for 9,136 shares of common stock.
NASDAQ
Kristine M. Ball, a Director at Oruka Therapeutics, Inc., acquired stock options for 9,136 shares.
NASDAQ
Fairmount Funds Management LLC and associated entities report the grant of stock options to a director, with vesting commencing June 2, 2026.
NASDAQ
Oruka Therapeutics Director Carl Dambkowski executed a series of option exercises and stock sales totaling 105,000 shares under a pre-arranged trading plan.
NASDAQ
Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.
NASDAQ
Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.